Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (Nasdaq:XENE) has announced that President Ian Mortimer and CFO Sherry Aulin will participate in fireside chats and one-on-one meetings at upcoming investor conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 14, the Stifel 2022 Healthcare Conference on November 15, and the Jefferies London Healthcare Conference on November 17. These presentations aim to engage investors and provide insights into the company’s developments in neurology therapeutics. Additional information can be found on their investors' website.
Xenon Pharmaceuticals has launched its Phase 3 program for XEN1101, initiating the X-TOLE2 clinical trial focused on treating epilepsy. The company maintains a strong financial position with approximately $752 million in cash, ensuring funding for operations through 2026. Despite a significant drop in third-quarter revenue from $8.1 million to $0.1 million due to the end of a collaboration with Neurocrine Biosciences and no milestone payments, R&D expenses have increased to $29.4 million. A conference call to discuss these updates is scheduled for today.
Xenon Pharmaceuticals (NASDAQ:XENE) appointed Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. DiFabio joins during a critical time as the company advances multiple late-stage clinical programs aimed at commercializing epilepsy therapeutics. With extensive experience in the life sciences sector, she previously held senior legal roles at various biopharmaceutical firms, including Biogen and Repertoire Immune Medicines. Her role will focus on enhancing Xenon’s legal framework and supporting its strategic goals in neurology therapeutics.
Xenon Pharmaceuticals has initiated its Phase 3 program for XEN1101 by launching the X-TOLE2 clinical trial, targeted at treating adult patients with focal epilepsy. This follows positive Phase 2b results and successful discussions with the FDA regarding trial design. The X-TOLE2 and its parallel study, X-TOLE3, aim to evaluate XEN1101's efficacy as an adjunctive treatment, involving approximately 360 patients each. Successful outcomes could lead to a New Drug Application submission. The program reflects Xenon's commitment to addressing unmet medical needs in epilepsy treatment.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its third quarter 2022 financial results on November 8, 2022, after U.S. markets close. The company is focused on developing innovative therapies for neurological disorders, particularly epilepsy. A live conference call and audio webcast will take place at 4:30 PM ET on the same day. Investors can register for participation to receive dial-in details. Xenon is committed to addressing high unmet medical needs in the neurology sector.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will participate in one-on-one investor meetings and a fireside chat at the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022. The fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET, featuring President and CEO Ian Mortimer and CCO Chris Von Seggern as presenters. A webcast will be available in the 'Investors' section of Xenon's website, with replays posted afterward. Xenon focuses on developing therapeutics for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 2022 results, highlighting a cash balance of $788.2 million and a cash runway extended into 2026 following a successful equity offering. The company plans to initiate the XEN1101 Phase 3 program, including the 'X-TOLE2' trial, in the second half of 2022. Recent analyses show XEN1101 rapidly reduced focal onset seizure frequency in prior trials. However, total revenue fell to $0.5 million from $2.2 million year-over-year, contributing to a net loss of $31.2 million, up from $22.1 million in Q2 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its Q2 2022 financial and operational results after U.S. markets close on August 9, 2022. The conference call and webcast will be held at 4:30 PM Eastern Time the same day, providing updates on the company’s performance in developing therapeutics for neurological disorders, focusing on epilepsy. Investors can access the live webcast on Xenon's website, with a replay available afterward. The announcement underscores Xenon's commitment to addressing high unmet medical needs in neurology.
Xenon Pharmaceuticals (Nasdaq:XENE) will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, in New York, NY. The company is focused on developing innovative therapeutics for neurological disorders, particularly in the area of epilepsy. A webcast of their fireside chat presentation will be available on their Investors section of the website. Xenon aims to address significant unmet medical needs through its clinical-stage product pipeline.
Xenon Pharmaceuticals has successfully closed its underwritten public offering of 9,098,362 common shares, raising approximately $287.5 million in gross proceeds. The offering included 1,229,508 shares from the underwriters’ option and 327,868 pre-funded warrants. Each common share was priced at $30.50, while pre-funded warrants were offered at $30.4999 with an exercise price of $0.0001. Major underwriters for this offering included Jefferies, J.P. Morgan, SVB Securities, and Stifel.